BTBP(SH:600161)2017-10-10 16:00Financial Performance - The company expects a net profit attributable to shareholders for the period from January 1 to September 30, 2017, to increase by approximately 474% compared to the same period last year (statutory disclosure data) and by approximately 483% compared to the restated data [2]. - The net profit attributable to shareholders for the period is expected to be 328.70 million yuan, an increase of 14.83% compared to the same period last year (statutory disclosure data) and 15.81% compared to the restated data [3]. Revenue Growth - The company's blood products business revenue and net profit both maintained growth, achieving an operating income of 1,071.86 million yuan, an increase of 18.09% compared to the same period last year (statutory disclosure data) and 13.56% compared to the restated data [3]. Investment Income - The company realized an investment income of 782 million yuan (pre-tax) from the transfer of 100% equity in Beijing Beisheng Research Biological Products Co., Ltd. and 51% equity in Changchun Qijian Biological Products Co., Ltd. [3].